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Abstract: Heart valve disease (HVD) is a globally increasing problem and accounts for 
thousands of deaths yearly. Currently end-stage HVD can only be treated by total valve 
replacement, however with major drawbacks. To overcome the limitations of conventional 
substitutes, a new clinical approach based on cell colonization of artificially manufactured 
heart valves has been developed. Even though this attempt seems promising, a confluent 
and stable cell layer has not yet been achieved due to the high stresses present in this area 
of the human heart. This study describes a bioreactor with a new approach to cell 
conditioning of tissue engineered heart valves. The bioreactor provides a low pulsatile flow 
that grants the correct opening and closing of the valve without high shear stresses. The 
flow rate can be regulated allowing a steady and sensitive conditioning process. 
Furthermore, the correct functioning of the valve can be monitored by endoscope 
surveillance in real-time. The tubeless and modular design allows an accurate, simple and 
faultless assembly of the reactor in a laminar flow chamber. It can be concluded that the 
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bioreactor provides a strong tool for dynamic pre-conditioning and monitoring of colonized 
heart valve prostheses physiologically exposed to shear stress. 
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1. Introduction 
The incidence and prevalence of heart valve disease is increasing worldwide. Up to 300,000 heart 
valves [1] are replaced each year and although valve repair is currently the preferred method of treating 
patients with severe heart disease, the predominant treatment for end-stage valvular heart disease is 
valve replacement [2]. As cardiac tissue is highly specialized and, in contrast to striated muscles such 
as biceps and quadriceps, not capable of repairing itself, valve replacement is often the only 
option [2,3]. At present, three types of heart valves are in clinical use: mechanical, biological and 
homograft and each type has severe limitations [4]. The consequences are severe, especially for 
pediatric patients. Approximately 2% of infants suffer from heart valve disease and therefore have to 
undergo multiple surgical or interventional procedures to restore the functionality of the replaced or 
reconstructed vessel [5]. A new approach to a better solution is made by tissue engineering. Tissue 
engineering combines the principles and methods of engineering and life science for the development 
of biological substitutes to restore, maintain or improve tissue functions [6]. The desirable 
characteristics of a heart valve grown in vitro would basically be a stable geometry with a potential for 
growth and regeneration within the patient [3]. There are two possibilities to profit from the 
advantages of tissue engineering. Either the whole valve can be engineered from human cells or a 
scaffold can be seeded with cell layers [2]. The creation of the whole valve has never shown promising 
results so far [7]. First, the necessary stability to withstand the high stresses cannot be reached so far. 
Secondly, the cultivation of such large amounts of cells needed has not been accomplished yet. 
Therefore research is mainly focusing on cell seeding of synthetic valves at the moment. Depending 
whether pediatric or adult patient should be treated, several scaffold materials are under investigation. 
Synthetic degradable polymers like polyglycolic acid (PGA) or polylactid acid (PLA) undergo 
degradation after implantation while an ECM is formed by colonized cells [8], which seems beneficial 
for growing pediatric patients. However, degradable polymers could denature in rates not matching 
those for tissue formation and release degradation products which affect biocompatibility [9]. 
Synthetic, non-degradable polymers like polyurethane (PU) are mainly characterized by their structural 
resistance, non-immunogenic and anti-thrombotic properties [10] favorable for the therapy of adult 
patients. However, a large challenge is the creation of a stable and confluent endothelial layer on valve 
scaffolds [3]. To enable the proliferation and differentiation of highly complicated cell structures like 
the endothelium, the cells have to be cultivated in bioreactors. The general idea is to provide a similar 
environment, including not only pH, temperature and other “classical” factors, but also stress  
exposure [11]. In the human body, cells are permanently subjected to and stimulated by mechanical, 
electrical, and chemical signals and gradients that influence their behavior, phenotype, shape, 
properties, and the proliferation rate [12]. Bioreactors represent the ideal possibility to study such 
effects on the generation of tissues. It has been found, that, if these signals are absent or improperly 




chosen, cells only poorly proliferate and cannot form organized tissues [13]. The cells dedifferentiate 
and no extracellular matrix (ECM) is established. To achieve a good quality ECM, mechanical stress is 
essential [12]. Therefore, specific bioreactors are indispensable for creation and regeneration of 
complex 3D tissue structures. Another valuable tool of a bioreactor is the possibility of perfusion. By 
perfusing culture medium directly through the pores of a cell-seeded 3D scaffold, thereby reducing 
mass transfer limitations both at the construct periphery and within its internal pores, metabolites can 
be transported into deeper cell-layers and cell survival, growth and function can be drastically 
enhanced. In conclusion, supplying metabolites, removing catabolites, maintaining temperature, 
establishing and monitoring pH, applying mechanical stresses that stimulate the formation of the ECM, 
and allowing cohesion between cells are the main functions that a bioreactor has to provide [14]. The 
aim of this study was to develop a new bioreactor which simulates physiological conditions and 
provides the possibility to gradually increase shear stress induced to the endothelial layer. 
2. Results and Discussion 
2.1. Bioreactor Assembly 
As shown in Figure 1, the pulsatile conditioning bioreactor consists of a core unit with Teflon® 
support (TS) (a); an actuation unit (b) and a monitoring unit (c) built from several assembly groups. 
Figure 1. Bioreactor assembly: The bioreactor-system can be divided in the core unit with 
TS (a); the actuation unit (b) and the monitoring unit (c) Scale bar = 100 mm. 
 
 
The bioreactor was designed to precondition polyurethane heart valve (PUHV). Earlier approaches 
attempted to create artificial heart valves by statically seeding of autologous cells on PU heart valves 
followed by shear stress exposure. Due to this sudden change of environment, the cells are not able to 
adapt to the new conditions and are lost by flow rates far below physiologic conditions. Numerous 
bioreactors for conditioning of heart valves by flow are previously described [13,15–19]. However, 
these bioreactors have major drawbacks. All these systems have a bulky design [20] and work with a 




lot of tubes [13,21] and screws [3]. In contrast, the bioreactor presented in this study has a compact and 
clearly arranged design and avoids the use of screws in the sterilized parts for an easy assembly of the 
bioreactor. Due to the need for sterility, this bioreactor was designed to be assembled in a laminar flow 
cabinet without any further tools like screwdrivers, etc.  
2.2. Core Unit 
As mentioned before, another drawback of existing bioreactors is tubing. The usage of tubes is a 
huge expense factor. Since the tubes have to be sterile, disposable tubes have to be used and have to be 
changed after every conditioning phase, which leads to high running costs. The second and more 
severe disadvantage of tubes is that they do not have any junctions. The lack of junctions leads to 
complicated methods of fixing and is immensely increasing the risk of infection. Furthermore, the 
fixing of the tubes demands the use of special tools again. Our bioreactor completely relinquishes 
tubing. While this may lead to slightly higher immediate nonrecurring manufacturing costs, the 
running costs as well as the risk of infection are minimized.  
Figure 2. Core unit of the bioreactor: Casing (1); lid (2); disc (3); separation plate (4); 
valve (5); TS (6); cleanout (7); gas filters (8); three-way stopcock (9). The core unit 
contains the TS, provides a circulating flow through the PUHV and allows monitoring and 
exchange of culture medium. Scale bar = 50 mm. 
 
 
The core unit (Figure 2) is the central part of the reactor and provides a stable retaining fixture, in 
which the TS can be fixed to keep PUHV orientation upwards, meaning that the leaflets open upwards. 
The fluid is channeled upwards through the valve and circulates back through the outside of the valve. 
The main task of the valve-leaflets is to prevent any backflow through the valve. Therefore a possibility 
for the recirculation of the medium is provided. Moreover it is granted that the flow through the valve 
(the up-flow) is strong enough to open the valves correctly. The flow is channeled to ensure sufficient 
pressure and flow volume. The reactor further offers medium cleanout by a luer-lock-connector during 
the process to avoid cell damage due to flow break. This connector can also be used for pressure 
measurements. Manufacturing of the core unit from acrylic glass provides optical transparency for 
macroscopic observation of processes within the unit. Physiological conditions (37 °C/5% CO2) are 




provided by integrating the bioreactor in a standard incubator. Sterile filters connected by luer-locks to 
the lid secure CO2-exchange. On one luer-lock a three-way stopcock is interposed to allow medium 
and cell addition.  
The TS (Figure 3), consisting of a bottom plate, a lid with variable inserts and four connecting bars, 
was designed to avoid heart valve deformation during conditioning and to compensate loss of height 
after sampling. 
Figure 3. Teflon® support (TS) for heart valve fixation: The TS (a) consists of a bottom 
plate (1), four bars (2) and a lid (3). The lid can be assembled by a screw (6) with three 
different inserts (b) to vary the distance between the valves fixing points (4,5) while 
maintaining a constant length of the TS. Scale bars = 20 mm. 
 
2.3. Actuation Unit 
The actuation unit (Figure 4) is the most complex part of the bioreactor and provides a pulsatile 
flow for the core unit. Therefore, a special engine was designed. A speed regulator (7) is connected to 
the motor (1) for a continuously alignment of 0–60 rpm. The motor turns the cam (2) which is fixed to 
the piston rod (3). The piston rod is conducted in the cylinder (4) which leads to a horizontal 
movement of the piston in the cylinder. The cylinder is connected to the air chamber (5) of the 
bioreactor, which mainly consists of an air chamber and a membrane (6) (free movement: d = 70 mm), 
balancing displaced volume. Calculated flow constitutes 31,500 mm3 per cycle, which adds up to about 
2 L/min. To avoid membrane overstretching, a flow of 31,000 mm3 (≈1.86 L/min) was applied. 
2.4. Monitoring Unit 
The complicate process of conditioning heart valves requires monitoring and maintaining the 
correct framework conditions. Temperature, pH and CO2 concentration have to be controlled as well as 
the correct opening and closing of heart valve leaflets. While previous reactors controlled temperature, 
CO2 and the cellular growth medium [17], options to monitor the correct functioning of the valve have 
not been provided. Because our bioreactor is compact enough to fit into a standard incubator, 
temperature and CO2 concentration do not have to be controlled by the bioreactor itself.  
Moreover, the monitoring unit (Figure 5) of our bioreactor allows heart valve observation with a 
technical endoscope. The endoscope is strictly isolated from the sterile core unit to keep the risk of 




infection to a minimum. Two concentric holes with different diameters in the cap enable the insertion of a 
thin glass plate (1). The glass plate is pressed against the rim by a cylinder (2) which is screwed into the 
cap. The cylinder locks the glass plate into position and also serves as an endoscope fixing. A gasket ring is 
attached at the bottom of the cylinder, to protect the glass plate and to enable a maximal contact pressure. 
The endoscope can be fixed in the cylinder by a retaining screw (3) to ensure that it is in a locked position. 
The attached three-way stopcock (4) allows ingestion of culture medium or cell suspension. 
Figure 4. Actuation unit of the bioreactor: Motor connected to an eccentric (1); connection 
rod (2); piston (3); cylinder (4); air chamber (5); fixing coil (6); speed regulator (7); base 
plate (8). The actuation unit generates a pulsatile flow and provides a compact and stable 
base for the whole bioreactor system. The flow is adjustable from one to sixty pulses per 
minute. Scale bar = 50 mm. 
 
Figure 5. Monitoring unit of the bioreactor: Glass plate (1); cylinder (2); fixing screw (3); 
luer-lock with attached three-way stopcock (4). The monitoring unit grants a stable and secure 
way to observe the PUHV without risk of contamination. A seal ring on top of the glass plate 
ensures a sealed off environment inside the bioreactor while providing a clear view on the 
valve leaflets. The endoscope can be secured with the fixing screw. Scale bar = 50 mm. 
 
2.5. Bioreactor Function 
A pulsatile flow is created in the core unit without any fluid exchange between the core unit and the 
actuation unit as well as without any contact of the medium with unsterile parts. 




The bioreactor activity is controlled and regulated by the speed regulator adjusting motor velocity. 
The motor is driving the extender wheel which transfers the rotation into a linear movement of the 
piston. The piston increases the pressure in the air chamber during the forward movement and 
decreases it while moving backwards. Consequently, the membrane is moved up and down each cycle, 
resulting in a flow (Figure 6) of culture media in the upper chamber. To overcome the problem of flow 
channeling, the bioreactor is equipped with a valve (1), working in opposite direction of the PUHV. 
Every time the actuation membrane is curved upwards, the medium flow moves the membrane against 
the separating plate, resulting in a closure of the eight smaller holes (2). The whole flow is directed 
through the main flow drill hole (MFDH) and passes the PUHV at opened leaflets. When the actuation 
membrane is lowered again, the pressure in the lower chamber of the core unit decreases and the  
up-flow stops. The leaflets seal the heart valve, the membrane glides back into its resting position and 
the medium flows back through the eight smaller holes. The disc (3) directs the flow of the medium 
along the casing wall and avoids a medium flow along the external wall of the PUHV, preventing 
cellular coverage from mechanical stress. 
Figure 6. Flow circulation: During the up-flow, the valve (1) is pushed upwards and seals 
the small holes (2). Culture medium flows upwards through the valve and backwards through 
the small holes. A backflow through the valve is prevented by PUHVs leaflets. The disc (3) 
prevents medium backflow along the external wall of the PUHV. Scale bar = 50 mm. 
 




The medium runs upwards through the MFDH in the center and streams back through the smaller 
holes. To provide a stable retaining fixture for the TS, the MFDH has an offset so that the TS can be 
slid into the CU. A second offset was added, to grant a constant diameter in the MFDH to avoid any 
turbulence. Due to this form closure, the TS is horizontally located into position. The TS is clamped by 
the cap of the reactor which is screwed on top of the casing and thereby arrests the cage in vertical 
direction. Between the TS and the cap a disc is integrated. On the top of the disc, a joint ring is 
arranged, which dampens the tension and thereby protects the Teflon support. 
2.6. Bioreactor Sterility 
Culture medium was checked during the bioreactor run at 5 days and 10 days for signs of 
contamination by conventional streak samples. Medium was examined for aerobic growth, particularly 
pathogenic saccharomyces or blastomycetes. After 15 days of observation, the air chamber was 
checked for fluids. Microbiological analysis and macroscopically inspection showed negative results, 
indicating sterile operation conditions if handled correctly. 
2.7. Bioreactor Functionality 
Appliance, function and handling of the bioreactor were tested and showed the desired results. The 
whole bioreactor system worked properly and in a satisfactory manner. The simple and tubeless design 
led to a great acceptance of the bioreactor by the users. The complete omission of tubes leads to a 
failsafe design of the bioreactor. All components of this bioreactor can only be assembled in one 
specific and clear way. The risk of reverse connections and the resulting destruction of the heart valves 
are eliminated in this design since there is only one possible way to assemble the bioreactor. However, 
most of the state-of-the-art bioreactors require screws and tubes for assembly. This increases the 
required time and complexity for assembly as well as the risk of errors [22–30]. The compact design 
and mounting on a baseplate of our bioreactor grants stability during preconditioning and allows an 
easy and quick handling and transportation. Other bioreactors found in literature consist of many loose 
components without any stabilizing structure [22–25,29]. 
As a result of our assembly, the endoscope has clear vision of the upper side of the heart valve and 
the correct opening and closing of the valve leaflets can be accurately monitored. The endoscope can 
be connected to a computer via USB. Thus, no visual display or saving unit has to be attached to the 
bioreactor and the reactor design remains compact and easy to handle. The acquired data can be edited, 
saved or simply streamed on the computer. Visual control of the correct valve function is a helpful and 
important feature of this bioreactor. Most of previously described bioreactors are not equipped with a 
monitoring unit. With these bioreactors, monitoring is either only possible by visual inspection if the 
incubator is opened [27,28,30] or not at all [22–25,29]. 
To ensure that the tissue engineered heart valve is preconditioned in a correct manner, the designed 
mechanism was examined. The bending of the membrane as well as the second valve worked as 
intended which resulted in the expected circling flow in the core unit. Testing the bioreactor with an 
unseeded PUHV showed that the pulsatile flow through the bioreactor is strong enough to induce a 
correct opening and closing of the valve leaflets (Figure 7). After quantification, an opening area of 
approximately 83% was determined. Thus, the designed actuation unit proofed sufficient for the 




preconditioning phase and no external pump is required. Most of the bioreactors found in literature 
rely on external actuators. Those require large tubes to connect the bioreactor inside the incubator with 
the actuation unit outside increasing the risk of contamination [22–28]. 
To evaluate the long-term behavior of the preconditioning system, the bioreactor was tested for  
5 days. This survey showed that the bioreactor is capable of long-term loading. The motor withstood 
the high humidity and temperature in the incubator without any problems and showed no signs of 
fatigue. Likewise, the membrane withstood the high and continuous bending stresses. After 15 days of 
testing, visual examination of the membrane showed no signs of corrosion or rupture. The membrane 
should be exchanged preventively after three preconditioning cycles to avoid dynamic and elastic 
fatigue resulting in membrane rupture and consequently in contamination of the sterile compartment. 
Another important difference between this bioreactor and the reactors found in literature [20] is that 
this bioreactor is not only designed for the actual conditioning process. This bioreactor was designed to 
be an intermediate step between the seeding and evaluation procedures. It allows slowly increasing the 
stress on the PUHV to grant the cells the possibility to adapt to shear stress and to develop an ECM. In 
this context, Ramaswamy et al. reported from a large collagen mass production after use of simulated 
pulmonary artery conditions using an organ-level heart valve bioreactor [22]. Zeltinger et al. described 
the stimulation of human dermal fibroblasts seeded onto a decellularized porcine matrix by a 
pneumatic flow bioreactor, resulting in the synthesis of ECM proteins [27]. For the fabrication of 
vascular grafts, Syedain et al. and Tschoeke et al. demonstrated the expression of collagen and other 
ECM components by human dermal fibroblast and ovine arterial myofibroblasts in fibrin gel [28,31]. 
However, complications such as thrombosis after the implantation of artificial grafts are caused in part 
by the lack of an intact endothelium [32]. To enable the development of an ECM and the formation of 
an endothelium, PUHV was consecutively seeded with fibroblasts (FB) and endothelial cells (EC) and 
were conditioned as described in the experimental section. Scanning electron microscopic (SEM) 
analysis (Figure 8) of native PUHV (a) demonstrated randomly orientated fibers resulting in a rough 
surface. PUHV showed a confluent cellular coverage prior conditioning (b) and after conditioning (c). 
In addition, cobblestone morphology indicates an intact endothelial layer after conditioning. Moreover, 
seeded PUHV exposed to flow revealed a cell alignment in flow direction. This is in contrast to results 
generated by Sierad et al. [26] demonstrating that EC did not completely cover all areas of the valve 
after seeding and perfusion at 600 mL/min for 17 d in a pulsatile conditioning system. 
Immunohistochemical analysis was carried out to compare fibroblast and endothelial layers prior 
and after conditioning. As shown in Figure 9, immunohistochemical analysis of PUHV prior 
conditioning revealed a positive staining for CD31 and TE-7, indicating a confluent coverage with FB 
(a, purple) and EC (b, brown). After conditioning, a multilayer of FB (c, brown) with an endothelial 
lining (d; brown) was observed. Cell nuclei were stained with hemalaun (a–d, purple). 




Figure 7. Assessment of bioreactor functionality by endoscopic observation: Functional 
efficiency of the bioreactor was demonstrated by perfect closure (a) and opening of the 
heart valve (b–d). Scale bars = 5 mm. 
 
 
Figure 8. SEM analysis of seeded PUHV. Native (a) samples of PUHV showed disordered 
fibers resulting in a rough surface. PUHV revealed a confluent endothelial layer after 
seeding (b) with an EC alignment in flow direction after conditioning (c). Scale bars:  
a = 30 µm, b, c = 100 µm. 
 




Figure 9. IHC analysis of seeded PUHV. Prior conditioning, seeded PUHV revealed a 
confluent coverage with FB (a) purple; and EC (b) brown. After conditioning PUHV also 
show a dense layer of FB (a) brown, arrows; and EC (b) brown, arrows. Cell nuclei were 
stained with hemalaun (a–d) purple. Scale bars = 50 µm (a–d). 
 
3. Experimental Section 
3.1. Construction of the Bioreactor 
A three-dimensional model of the bioreactor was designed using CATIA V5R19 software 
(IndustrieHansa Consulting & Engineering GmbH, Munich, Germany). The bioreactor was divided in 
eight assembly groups (Table 1) and was manufactured in-house. 
Table 1. Bioreactor assembly groups. The bioreactor was divided in eight assembly groups 
with several components: membrane carrier (A); valve (B); core unit (C); monitoring 
unit (D); actuator (E); eccentric (F); motor unit (G) and base unit (H). 
Group Description Components 
A Membrane Carrier 2 aluminum coils, 4 fixing pins, 1 membrane, 1 seal ring 
B Valve 1 valve membrane, 4 guiding rings 
C Core Unit 1 housing, 1 air chamber, assembly A, assembly B, 1 lid,  
1 Teflon® support 
D Monitoring Unit 1 endoscope cylinder, glass plate, fixing screw 
E Actuator 1 cylinder, piston, 2 seal rings, cylinder lid 
F Eccentric 1 extender wheel, 1 piston rod, 2 securing pins, 2 plates 
G Motor Unit 2 stands, 1 motor housing, 1 motor 
H Base Unit 1 base plate, 1 reactor stand 




A membrane carrier is designed to tighten the actuation membrane which is displacing the medium 
in the core unit. It consists of two aluminum coils with an outer diameter D = 102 mm, an inner 
diameter d = 70 mm and a height h = 8 mm. The membrane (D = 100 mm, thickness = 1 mm) is placed 
between the two coils. Four fixing pins tighten the aluminum coils and secure the membrane carrier 
against rotation. This way the attached seal ring is protected and a tight seal is guaranteed. The coils as 
well as the fixing pins are made of aluminum (Rau GmbH & Co.KG, Munich, Germany). Membrane and 
the seal ring consist of room temperature vulcanization (RTV) silicone (Sahlberg GmbH & Co.KG, 
Munich, Germany). 
The membrane carrier, a valve and a cylindric air chamber (D = 120 mm, d = 70 mm, h = 60 mm) 
form the core unit. The valve consists of a silicone membrane (D = 72 mm, thickness = 1 mm) and four 
guiding rings (D = 10 mm, h = 5 mm) made of Teflon® (Sahlberg GmbH & Co.KG, Munich, Germany). 
The valve is attached to the housing by four stainless steel screws (Keller & Kalmbach GmbH, 
Unterschleißheim, Germany; M6). The housing, made of acrylic glass (Sahlberg GmbH & Co.KG, 
Munich, Germany), can be described as a cylinder (D = 105 mm, h = 130 mm) divided in two 
chambers (d = 70 mm, h = 30 mm; d = 90 mm, h = 88 mm) by an offset. The barrier provides a 
fixation for a PUHV TS in the upper chamber and the valve in the lower chamber. The TS consist of a 
bottom plate (D = 48 mm, d = 27 mm, h = 13 mm) and a lid (D = 48 mm, d = 21 mm, h = 13 mm) with 
variable inserts connected by four bars (D = 6 mm, h = 55 mm). The chambers are connected by a 
MFDH (D = 27 mm) positioned in the center of the cylinder and eight smaller holes (D = 7 mm), 
circular arranged around the center. A rim (D = 102 mm) allows the placement of the membrane 
carrier. A horizontal bore hole (D = 15 mm, h = 23 mm) provides the ability to attach the actuator. The 
upper part of the core unit is sealed by a lid (D = 120 mm, h = 20 mm) made of acrylic glass with a 
centered bore hole (D = 18 mm, M27 thread) for endoscopic monitoring. 
The monitoring unit is an assembly of an endoscope cylinder (D = 27 mm, d = 21 mm, h = 100 mm), a 
glass plate (Sarstedt AG & Co., Nümbrecht, Germany, D = 24 mm, h = 1 mm) and a fixing screw. The 
glass plate covers the lid hole and is secured by the endoscope cylinder. A horizontal thread (M6) 
allows securing the endoscope with the fixing screw. 
The actuator consists of a cylinder, a piston, two seal rings and a cylinder lid. The cylinder  
(D = 45 mm, d = 40 mm, length l = 95 mm) provides six bores for fixation to the air chamber with 
stainless screws (Keller & Kalmbach GmbH, Unterschleißheim, Germany; M5). The inner diameter of 
the cylinder is reduced to 15 mm at the intake of the air chamber due to geometrical restrictions. The 
piston has a total length of 78 mm. The piston head (l = 16 mm, D = 28 mm) provides space for two 
seal rings. The piston shaft (l = 62 mm, D = 14 mm) provides a through hole (D = 6 mm) for the 
attachment of an eccentric. The cylinder lid (D = 40 mm, h = 4 mm) with a center bore (D = 16mm) 
provides space for the piston shaft. Cylinder, piston as well as cylinder lid are fabricated  
from aluminum. 
The piston is connected to an eccentric (D = 56 mm, h = 6 mm) by a piston rod (l = 60 mm, width  
w = 10 mm, h = 6 mm) with a securing pin (D = 6 mm, l = 21 mm). To minimize the friction between 
the piston rod and the eccentric, a Teflon® plate (D = 12 mm, d = 6 mm, h = 2 mm) was added 
interjacent. A thread (M3) assures a frictionless fixation to the motor. Piston rod and extender wheel 
are manufactured from aluminum. For the securing pins and plates, Teflon® was chosen to minimize 
friction. The extender wheel is directly connected to the motor unit. The commercial available motor 




(RB-35GM; Modelcraft Inc., Blaine, WA, USA) with a copper coil and an iron shaft provides  
60 revolutions per minute (rpm) and was connected to a speed regulator (H-Tronic GmbH, Hirschau, 
Germany) adjustable from 0 to 60 rpm. In order to avoid corrosion due to humidity, all metals are 
coated with an anti-corrosion layer. In addition, speed regulator and motor are placed in housings made 
of plastic (Sahlberg GmbH & Co.KG, Munich, Germany; l = 150 mm, w = 80 mm, h = 40 mm) and 
aluminum (Rau GmbH & Co.KG, Munich, Germany; D = 50 mm, l = 70 mm), respectively.  
The base unit consists of a rectangular base plate (l = 260 mm, w = 240 mm, h = 5 mm) and a 
cylindric reactor stand (D = 130 mm, h = 18 mm) with a countersink of 3.5 mm (D = 120 mm) to fit 
the air chamber. Base plate and reactor stand were manufactured from polyvinylchloride (PVC; 
Sahlberg GmbH & Co.KG, Munich, Germany); the air chamber was made of acrylic glass. 
3.2. Sterilization of the Bioreactor 
All bioreactor parts which are in contact with culture medium (group A-D) were disassembled and 
sterilized by formaldehyde deposition at 60–70 °C for 7 h. Medium samples were aseptically taken 5 days, 
10 days and 15 days after bioreactor actuation in a standard incubator at 37 °C/5% CO2. Sterility was 
examined by conventional microbiological evaluation methods (Max-von-Pettenkofer-Institut für 
Hygiene und medizinische Mikrobiologie, University of Munich, Munich, Germany). In addition, the 
bioreactor was visually inspected and the air chamber was examined for traces of culture medium. 
3.3. Seeding of PUHV 
The PUHV were sutured to the TS (a) and were seeded as previously described [33]. Briefly, PUHV 
were successively seeded with human vascular FB (1.5 × 106/cm2) and EC (1.5 × 106/cm2). For each 
cell type, a dynamic seeding procedure was performed for 24 h at 37 °C/5% CO2 using a  
3D-rotating bioreactor (Figure 8a; running phase: 2.5 min; static phase: 30 min) followed by a static 
resting period of 6 d at 37 °C/5% CO2 in a glass container (Figure 10b). Medium was exchanged every 
2–3 days. 
Figure 10. Seeding of PUHV. PUHV were sutured to the TS (a) and were consecutively 
seeded with human vascular fibroblasts and endothelial cells using a 3D-rotating bioreactor 
(b) for 24 h at 37 °C/5% CO2. After the dynamic seeding procedure, PUHV were statically 
cultivated for 6 days at 37 °C/5% CO2 in a glass container (c). Scale bars: a = 10 mm,  
b = 20 mm, c = 15 mm. 
 




3.4. Functionality Testing 
An unseeded PUHV sutured to the TS was continuously preconditioned for 5 days using the newly 
developed bioreactor. The actuation unit (assembly groups E, F, G) was checked for proper operation 
in the humid climate of a conventional incubator at 37 °C/5% CO2 by monitoring of piston and 
eccentric movement. Furthermore, the actuation unit was examined for traces of abrasion and wear and 
the membranes were checked for ruptures. The quality of the images produced by the endoscope was 
evaluated. The endoscope was used to control the correct opening and closing of the PUHV during 
conditioning. The culture medium was visually examined on a regular basis to control the nutrient 
supply. For the analysis of the mechanical integrity and the conditioning efficiency of the cellular 
coating, seeded PUHV sutured to the TS was transferred under sterile conditions from the 3D-rotating 
seeding bioreactor to the newly developed pulsatile conditioning bioreactor and was continuously 
preconditioned at 750 mL/min for 2 days and 1,100 mL/min for 3 days. For analysis, samples of 
seeded PUHV were taken from the supravalvular, valvular and subvalvular region of the aortic wall as 
well as from the valvular leaflets.  
3.5. Scanning Electron Microscopy (SEM) 
Samples from PUHV were fixed in 456 mL aqua bidest (Ampuwa, Fresenius Kabi Deutschland 
GmbH, Bad Homburg, Germany) supplemented with 0.75 mL 1 N hydrochloric acid (Titrisol, Merck 
KGaA, Darmstadt, Germany), 43.5 mL glutaraldehyde (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany) and 5.65 g sodium cacodylate trihydrate (Sigma-Aldrich Chemie GmbH, Steinheim, 
Germany) at 4 °C for 48 h. The fixed specimens were dehydrated in an afferent ethanol series (30%, 
50%, 70% and 96% EtOH) and then placed in 100% acetone (Merck KGaA, Darmstadt, Germany). 
After critical point drying the samples were sputtered with gold for 180 s at 10–5 mbar and analyzed 
using a scanning electron microscope (Carl Zeiss Mikrolmaging GmBH, Göttingen, Germany). 
3.6. Immunohistochemistry (IHC)  
Immunohistochemical staining was performed to differentiate between FB and EC layers on the 
PUHV prior and after conditioning. Samples were fixed in 4% formaldehyde (Microcos GmbH, 
Garching, Germany) for 10 days at 4 °C and the stents were carefully removed. Paraffin-embedded 
specimens were sectioned at 10 µm and were stained for CD31 (0.09 µg/mL; Dianova GmbH, 
Hamburg, Germany) and TE-7 (2 µg/mL, Millipore Corporation BioScience Division, Temecula, CA, 
USA) using the HRP Detection System (Biozol GmbH, Eching, Germany) according to 
manufacturer’s protocol. Briefly, endogenous peroxidase activity was blocked using 0.12% H2O2 in 
PBS for 10 min at room temperature (RT). After incubation with the primary antibody overnight at  
4 °C, the samples were incubated with the biotinylated link for 10 min at RT. The cells were then 
incubated with HRP Streptavidin-label for 10 min at RT, followed by AEC labeling (Vector 
Laboratories, Inc., Burlingame, CA, USA) for another 10 min at RT. Cell nuclei were stained with 
Mayer’s hemalaun (Merck KGaA, Darmstadt, Germany; 1:4 in PBS). Negative controls for non-specific 
binding of the biotinylated link were performed by exclusion of the primary antibody. Sections were 
analyzed using bright field microscopy (Carl Zeiss Mikrolmaging GmBH, Göttingen, Germany).  





In conclusion, we demonstrated the successful development of a pulsatile bioreactor for the 
conditioning of PUHV to shear stress. Functional testing showed that the bioreactor worked properly. 
This bioreactor means a large step towards long-life PUHV. These valves would not only be highly 
biocompatible but also provide the possibility to self-repair, which would be a significant advantage 
against all other synthetic heart valves. These advantages combined with a nearly endless availability 
render PUHVs highly attractive for further researches. With the bioreactor described above, a new type 
of conditioning bioreactors is introduced. The most important features of this reactor are an easy 
assembly, a sensitive regulation of stress and detailed monitoring combined in a compact design with 
high modularity. As a result of the introduction of a new step in tissue engineering, the preconditioning 
process, confluent and stable layers of autologous cells on synthetic or natural scaffold can be 
generated. This results in a gain of significance of tissue engineered heart valves in medical 
applications. The presented bioreactor was designed for PUHV-preconditioning. However, due to the 
modularity, the bioreactor system could be also used for multiple other applications. If the design is 
slightly readjusted, cardiovascular patches or vascular grafts could be perfused in this system. For 
these applications, only customized core units have to be designed. The actuation unit as well as the 
monitoring unit do not have to be changed and can be used for all designs, leading to a cost- and  
time-effective design and manufacturing process of new customized reactors.  
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